Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Barts Health NHS Trust, London, UK.
J Clin Endocrinol Metab. 2021 Oct 21;106(11):e4716-e4733. doi: 10.1210/clinem/dgab437.
Growth hormone insensitivity (GHI) in children is characterized by short stature, functional insulin-like growth factor (IGF)-I deficiency, and normal or elevated serum growth hormone (GH) concentrations. The clinical and genetic etiology of GHI is expanding.
We undertook genetic characterization of short stature patients referred with suspected GHI and features which overlapped with known GH-IGF-I axis defects.
Between 2008 and 2020, our center received 149 GHI referrals for genetic testing. Genetic analysis utilized a combination of candidate gene sequencing, whole exome sequencing, array comparative genomic hybridization, and a targeted whole genome short stature gene panel.
Genetic diagnoses were identified in 80/149 subjects (54%) with 45/80 (56%) having known GH-IGF-I axis defects (GHR n = 40, IGFALS n = 4, IGFIR n = 1). The remaining 35/80 (44%) had diagnoses of 3M syndrome (n = 10) (OBSL1 n = 7, CUL7 n = 2, and CCDC8 n = 1), Noonan syndrome (n = 4) (PTPN11 n = 2, SOS1 n = 1, and SOS2 n = 1), Silver-Russell syndrome (n = 2) (loss of methylation on chromosome 11p15 and uniparental disomy for chromosome 7), Class 3-5 copy number variations (n = 10), and disorders not previously associated with GHI (n = 9) (Barth syndrome, autoimmune lymphoproliferative syndrome, microcephalic osteodysplastic primordial dwarfism type II, achondroplasia, glycogen storage disease type IXb, lysinuric protein intolerance, multiminicore disease, macrocephaly, alopecia, cutis laxa, and scoliosis syndrome, and Bloom syndrome).
We report the wide range of diagnoses in 149 patients referred with suspected GHI, which emphasizes the need to recognize GHI as a spectrum of clinical entities in undiagnosed short stature patients. Detailed clinical and genetic assessment may identify a diagnosis and inform clinical management.
儿童生长激素不敏感(GHI)的特征是身材矮小、功能性胰岛素样生长因子(IGF)-I 缺乏以及血清生长激素(GH)浓度正常或升高。GHI 的临床和遗传病因正在不断扩大。
我们对因疑似 GHI 而转诊的身材矮小患者以及与已知 GH-IGF-I 轴缺陷重叠的特征进行了遗传特征分析。
在 2008 年至 2020 年间,我们中心共收到 149 例 GHI 患者的遗传检测转诊。遗传分析采用候选基因测序、全外显子组测序、比较基因组杂交阵列和靶向全基因组矮小基因面板相结合的方法。
在 149 例患者中,有 80 例(54%)确定了遗传诊断,其中 45 例(56%)患有已知的 GH-IGF-I 轴缺陷(GHR n=40,IGFALS n=4,IGFIR n=1)。其余 35 例(44%)诊断为 3M 综合征(n=10)(OBSL1 n=7,CCUL7 n=2,CCDC8 n=1)、Noonan 综合征(n=4)(PTPN11 n=2,SOS1 n=1,SOS2 n=1)、Silver-Russell 综合征(n=2)(11p15 染色体去甲基化和 7 号染色体单亲二倍体)、3-5 类拷贝数变异(n=10)和以前与 GHI 无关的疾病(n=9)(Barth 综合征、自身免疫性淋巴增生性综合征、小头畸形性骨发育不良 II 型、软骨发育不全、糖原贮积病 IXb 型、赖氨酸尿蛋白不耐受症、多核病、大头畸形、脱发、皮肤松弛和脊柱侧凸综合征和 Bloom 综合征)。
我们报告了 149 例因疑似 GHI 而转诊的患者的广泛诊断,这强调了在未确诊的身材矮小患者中,需要将 GHI 视为一系列临床实体。详细的临床和遗传评估可能会确定诊断并为临床管理提供信息。